CompletedPhase 3NCT02586805
Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
Studying Hereditary angioedema
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shire
- Principal Investigator
- Shire PhysicianShire
- Intervention
- DX-2930 - 300mg/2wk(drug)
- Enrollment
- 125 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2016 – 2017
Study locations (30)
- Clinical Research Center of Alabama, LLC, Birmingham, Alabama, United States
- Medical Research of Arizona, Scottsdale, Arizona, United States
- UC San Diego School of Medicine, San Diego, California, United States
- AIRE Medical of Los Angeles, Santa Monica, California, United States
- Allergy & Asthma Clinical Research, Walnut Creek, California, United States
- IMMUNOe International Health & Research Centers, Centennial, Colorado, United States
- Asthma and Allergy Associates, P.C., Colorado Springs, Colorado, United States
- University of South Florida, Tampa, Florida, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Institute of Asthma & Allergy, P.C., Chevy Chase, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University of Michigan Hospital and Health System, Ann Arbor, Michigan, United States
- Midwest Immunology Clinic, Plymouth, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Hudson-Essex Allergy, LLC, Belleville, New Jersey, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Dyax Corp.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02586805 on ClinicalTrials.govOther trials for Hereditary angioedema
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07298447Donidalorsen Treatment in Children With Hereditary AngioedemaIonis Pharmaceuticals, Inc.
- RECRUITINGNANCT07559630Single-center Randomized Controlled Trial of Rectal Arterial Embolization vs Band Ligation for the Treatment of Internal hemOrrhoidSJessica K. Stewart, MD
- RECRUITINGNCT07263685A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi ArabiaTakeda
- RECRUITINGPHASE3NCT07428499Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)ADARx Pharmaceuticals, Inc.
- RECRUITINGNANCT07251933A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple CountriesTakeda
- ENROLLING BY INVITATIONPHASE3NCT07204938A Long-Term Study of Navenibart in Participants With Hereditary AngioedemaAstria Therapeutics, Inc.
- RECRUITINGPHASE3NCT06960213STOP-HAE: A Phase 3 Study of ADX-324 in HAEADARx Pharmaceuticals, Inc.
- RECRUITINGNANCT07001280A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)CSL Behring